 |
217 Diseases |  |
228 Trials |
|
228 Trials |  |
3892 News |  |
| «12...2021222324252627282930...4950» |
- |||||||||| ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
New P3 trial, Surgery: A study to test the effect of chemotherapy before surgery compared to surgery alone in patients with high risk retroperitoneal sarcoma (EUDRACT) - Dec 1, 2020
P3, N=250, Ongoing, Sponsor: European Organisation for Research and Treatment of Cancer`EORTC AISBL/IVZW
- || cyclophosphamide intravenous / Generic mfg.
Clinical, Journal, HEOR: Individualized chemotherapy guided by the expression of ERCC1, RRM1, TUBB3, TYMS and TOP2A genes versus classic chemotherapy in the treatment of breast cancer: A comparative effectiveness study. (Pubmed Central) - Nov 28, 2020
The chemotherapy strategy guided by genetic detection was an independent protection factor for DFS [hazard ratio (HR)=0.389, 95% confidence interval (CI): 0.153, 0.989, P=0.047], but not an independent protection factor for OS (HR=0.340, 95% CI: 0.107, 1.078, P=0.067). The results indicate that the combined detection of ERCC1, RRM1, TUBB3, TYMS and TOP2A gene expression and use of the results to guide individualized chemotherapy can improve treatment efficacy and reduce unnecessary toxicity.
- || Clinical, Journal: Older versus younger adults with gastric cancer receiving perioperative treatment: Results from the CRITICS trial. (Pubmed Central) - Nov 25, 2020
P3
Perioperative treatment compliance, especially in the postoperative phase, was poorer in older adults compared with younger adults. As comparable proportions of patients underwent curative surgery, future studies should focus on neo-adjuvant treatment.
- | epirubicin / Generic mfg.
Journal: Melatonin protects against Epirubicin-induced ovarian damage. (Pubmed Central) - Nov 22, 2020
These results indicate melatonin protects against epirubicin-induced ovarian damage by reducing ROS-induced ERS. Therefore, melatonin has a therapeutic potential for the protection of ovarian function and preservation of fertility during chemotherapy.
- || Lynparza (olaparib) / Merck (MSD), AstraZeneca
Clinical, Journal, BRCA Biomarker, PARP Biomarker: Interstitial Pneumonia Caused by Olaparib during Treatment of Breast Cancer-A Case Report (Pubmed Central) - Nov 22, 2020
Subsequently, she was treated with cyclophosphamide/methotrexate/fluorouracil. It is necessary to consider interstitial pneumonia as an adverse effect of olaparib.
- || Clinical, Retrospective data, Journal: Effect of the Antiemetic Drug Olanzapine on Blood Sugar Levels in Patients Treated with Adjuvant or Neoadjuvant Chemotherapy for Breast Cancer (Pubmed Central) - Nov 22, 2020
Among the 95 patients with more than 2 PBS readings, no difference was observed in the incidence of increased PBS, regardless of the diabetic risk, before and after OLZ administration. This study therefore found that the short term use of OLZ as an antiemetic had little effect on PBS, suggesting that it can be used safely during treatment with AC or CEF.
- || tamoxifen / Generic mfg., paclitaxel / Generic mfg., irinotecan / Generic mfg.
Review, Journal: Systemic therapy for limited stage small cell lung carcinoma. (Pubmed Central) - Nov 21, 2020
Maintenance therapy following induction with chemotherapy, vandetanib and interferon-alpha have also been attempted...In this review, we discuss the various systemic therapy options in limited stage small cell lung carcinoma, from the historical regimens to the modern-day therapy and promising areas of research. We also discuss the role of growth factors, the optimal number of chemotherapy cycles, the use of prognostic and predictive factors, the optimal timing of chemotherapy and the treatment of special populations of patients including older patients, and patients with comorbidities.
- | fluorouracil topical / Generic mfg., doxorubicin hydrochloride / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Journal: A fully validated simple new method for environmental monitoring by surface sampling for cytotoxics. (Pubmed Central) - Nov 19, 2020
This new sensitive validated method for surface contamination studies of cytotoxics was successfully applied on different localizations in hospital. This approach is particularly suitable to assess occupational exposure risk to cytotoxic drugs.
- paclitaxel / Generic mfg.
[VIRTUAL] Paracrine signalling with stromal fibroblasts drives recovery of cancer cells after chemotherapy treatment (OnDemand) - Nov 19, 2020 - Abstract #SABCS2020SABCS_1344;
Our study unravels a novel paracrine communication between cancer cells and stromal fibroblasts that ultimately results in the escape of malignant cells to treatment, highlighting the importance of the TME in drug response. Targeting of this axis could potentially improve the outcome of breast cancer patients to CTX treatment.
- | epirubicin / Generic mfg.
Journal: Self-Assembled Dual-Targeted Epirubicin-Hybrid Polydopamine Nanoparticles for Combined Chemo-Photothermal Therapy of Triple-Negative Breast Cancer. (Pubmed Central) - Nov 18, 2020
The long-circulating and higher tumor accumulation of E/PCF-NPs resulted in complete ablation of breast tumor tissue through the enhanced photothermal effect by NIR laser irradiation-mediated cell apoptosis. E/PCF-NPs show enhanced anti-cancer effects due to synergistic effects of chemotherapy with photothermal therapy and may be potential therapeutic agents for cancer treatment.
- |||| epirubicin / Generic mfg.
Clinical: Yet another reason to NOT use epirubicin (at this point hopefully it’s already extinct)! Great job @LizzySmyth1! EGFR, along with FGFR2 and MET amps are viable targets for our GEA pts added to HER2. How to study this to make it real? 🤔 @KlempnerSam @SteveMaronMD @BassLab_DFCI (Twitter) - Nov 17, 2020
- | Trial primary completion date: NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) (clinicaltrials.gov) - Nov 13, 2020
P3, N=540, Recruiting, Sponsor: Cancer Trials Ireland
E/PCF-NPs show enhanced anti-cancer effects due to synergistic effects of chemotherapy with photothermal therapy and may be potential therapeutic agents for cancer treatment. Trial primary completion date: Jan 2024 --> Mar 2023
- ||| Halaven (eribulin mesylate) / Eisai
Trial completion, Enrollment change: Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 (clinicaltrials.gov) - Nov 13, 2020
P2, N=54, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jan 2024 --> Mar 2023 Active, not recruiting --> Completed | N=162 --> 54
- || cyclophosphamide intravenous / Generic mfg., docetaxel / Generic mfg.
Biomarker, Clinical, Journal: Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel. (Pubmed Central) - Nov 12, 2020
In silico analysis of miR-210-3p and Docetaxel targets provided evidence for a putative molecular cross-talk involving microtubule regulation, drug efflux metabolism and oxidative stress response. Overall, our data point to the miR-210-3p involvement in the response to therapeutic regimens including Docetaxel in sequential therapy with anthracyclines, suggesting it may represent a predictive biomarker in breast cancer patients.
- || Stimuvax (tecemotide) / EMD Serono, Seattle Genetics
Clinical, P2 data, Journal: Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34). (Pubmed Central) - Nov 12, 2020
Overall, our data point to the miR-210-3p involvement in the response to therapeutic regimens including Docetaxel in sequential therapy with anthracyclines, suggesting it may represent a predictive biomarker in breast cancer patients. Neoadjuvant tecemotide is safe, but does not improve RCB or pCR rates in patients receiving standard neoadjuvant therapy.
- | epirubicin / Generic mfg.
Journal: hnRNPA2B1 inhibits the exosomal export of miR-503 in endothelial cells. (Pubmed Central) - Nov 7, 2020
The chemotherapeutic drug epirubicin increases the exosomal export of miR-503 in endothelial cells...The combination of these processes culminates in the increased export of miR-503. These results suggest, for the first time, that RNA-binding proteins can negatively regulate the exosomal sorting of microRNAs.
- | fluorouracil topical / Generic mfg.
Journal: Endurance of erythrocyte series in chemotherapy. (Pubmed Central) - Nov 6, 2020
The average relative loss of hemoglobin is -11% after the first three cycles of treatment, with statistically significant differences in hemoglobin levels in favor of men. There are risk factors associated with higher average losses, such as age 65 years (statistically significant), body mass index (BMI) >25, cisplatin treatment (insufficient number of cases to reach statistical significance).
- | epirubicin / Generic mfg.
New trial: Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT) (clinicaltrials.gov) - Nov 6, 2020
P=N/A, N=98, Recruiting, Sponsor: Beijing Tsinghua Chang Gung Hospital
- || leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg.
Review, Journal: Locoregional gastric cancer: a narrative review of multidisciplinary management. (Pubmed Central) - Nov 5, 2020
While advanced locoregional gastric cancer continues to carry significant mortality, several recent studies have added to the armament of treatment options and have seen significant improvement in progression free and overall survival in this patient population. Ongoing studies into perioperative management continue to investigate alternative treatment options and best practice for locally advanced resectable gastric cancer.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Waldenström’s Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_2517;
Old age, low platelet, low albumin, high β-2 microglobulin, high LDH and secondary amyloidosis indicate worse prognosis in WM. These findings may provide guidance for management of WM and better prognostic stratification of risk-adapted treatment strategies.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Screening DNA-targeted anticancer drug in vitro based on cancer cells DNA-templated silver nanoclusters. (Pubmed Central) - Nov 4, 2020
The template of DNA-templated silver nanoclusters was extracted from human liver carcinoma cells directly, which can express the drug activities against cancer cells more direct than the normal cells DNA. The anti-tumor activities of the four drugs were validated by MTT and apoptotic assay as Mitoxantrone > Epirubicin > Daunorubicin > Adriamycin.
- || epirubicin / Generic mfg.
Clinical, Journal: Identification of differential gene expression related to epirubicin-induced cardiomyopathy in breast cancer patients. (Pubmed Central) - Nov 4, 2020
ALAS2 and the metabolic pathways which were involved may play an important role in the development of epirubicin-induced cardiomyopathy. ALAS2 may be useful as an early biomarker for epirubicin-induced cardiotoxicity detection.
- || epirubicin / Generic mfg.
Clinical, Journal: Outcomes and complications of Hyperthermic IntraVesical Chemotherapy using mitomycin C or epirubicin for patients with non-muscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure. (Pubmed Central) - Nov 3, 2020
No patients experienced Grade 4/5 adverse events. HIVEC can be considered a feasible option in BCG failure/intolerant NMIBC patients, avoiding or postponing radical cystectomy in some particular subclasses of patients.
- || Clinical, Journal: Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer. (Pubmed Central) - Nov 2, 2020
HIVEC can be considered a feasible option in BCG failure/intolerant NMIBC patients, avoiding or postponing radical cystectomy in some particular subclasses of patients. These findings seem to confirm the feasibility of NAC for clinically T3 and T4 non-metastatic GC and, despite no statistical significant difference was documented, suggest a trend for better activity and tolerability for the docetaxel-based regimen (DOC) compared to the epirubicin-based combination (EOF).
- || Herceptin (trastuzumab) / Roche, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical, P2 data, Journal: Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial. (Pubmed Central) - Nov 1, 2020
One patient died of sepsis secondary to pneumonia during FEC treatment. Neoadjuvant chemotherapy using nab-PTX with trastuzumab every 3 weeks followed by FEC was suitably tolerated and associated with a high pCR rate of 55% for patients with HER2-positive breast cancer.
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Clinical, P2 data, Journal: A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. (Pubmed Central) - Oct 30, 2020
Personalization of the T-DM1+P regimen could serve as a reasonable approach to minimize toxicity while maintaining efficacy. Trial registration ID: UMIN-CTR: UMIN000014649.
- cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Comparison of the efficacy of reiki versus sport as supportive care during neoadjuvant chemotherapy of early breast cancer: sub analysis of the randomized controlled reassure (Reiki as supportive treatment during chemotherapy of breast cancer) study () - Oct 30, 2020 - Abstract #ESGO2020ESGO_332;
Conclusion Reiki may pose a viable alternative medical treatment option to sport as a supportive therapy option to combat side effects of neoadjuvant Epirubicin, Cyclophosphamide and Taxane chemotherapy for breast cancer treatment. To better understand the beneficial influence of this therapy, further research is needed to compare Reiki with a control group receiving no additional therapy
- || epirubicin / Generic mfg.
Clinical, Journal: ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer. (Pubmed Central) - Oct 28, 2020
Our study demonstrated rs6484711 polymorphism regulating ABTB2 expression might predict efficacy to epirubicin based NAC in luminal A breast cancer patients. These results provided valuable information about potential role of genetic variations in individualized chemotherapy.
- | epirubicin / Generic mfg.
Journal: Epirubicin-loaded marine carrageenan oligosaccharide capped gold nanoparticle system for pH-triggered anticancer drug release. (Pubmed Central) - Oct 27, 2020
A new pH-triggered anticancer drug release was achieved by EPI-CAO-AuNPs system for the first time. The developed EPI-CAO-AuNPs nanosystem shows a promising prospect for pH-triggered delivery of antitumor drugs, and our work provides a new idea for targeted drug delivery by using biocompatible marine carbohydrates as nanomaterial.
- | paclitaxel / Generic mfg., epirubicin / Generic mfg.
Journal: Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylatedliposomal nanoparticle for breast cancer. (Pubmed Central) - Oct 27, 2020
Consequently, the ES-SSL-EPI/PTX significantly suppressed tumor growth in the MCF-7-derived tumor-bearing mouse model without inducing toxicity. These results suggested that the ES-SSL-EPI/PTX was a promising formulation for co-delivery of chemotherapeutics in the treatment of breast cancer.
- | epirubicin / Generic mfg.
Journal: Mechanism Investigation of Hyaluronidase-Combined Multistage Nanoparticles for Solid Tumor Penetration and Antitumor Effect. (Pubmed Central) - Oct 27, 2020
We here reported a tumoral microenvironment responsive multistage drug delivery system (NPs-EPI/HAase) which was formed layer by layer via electrostatic interaction with epirubicin (EPI)-loaded PEG-b-poly(2-(diisopropylamino)ethyl methacrylate)-b-poly(2-guanidinoethylmethacrylate) (mPEG-PDPA-PG, PEDG) micelles (NPs-EPI) and hyaluronidase (HAase)...Compared with NPs-EPI, the HAase coating group showed an enhanced tumoral drug delivery efficacy and inhibition of tumor growth. Overall, our studies demonstrated that coating nanoparticles with HAase can provide a simple but efficient strategy for nano-drug carriers to enhance solid tumor penetration and chemotherapeutic efficacy.
- | doxorubicin liposomal / Generic mfg.
Journal: Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance. (Pubmed Central) - Oct 25, 2020
Liposomal packaging of doxorubicin induced interferon-stimulated genes in association with lower cardiotoxicity, which is of high clinical importance in anticancer treatment. Our study identified potential mechanisms for rational development of strategies to mitigate anthracycline-induced cardiomyopathy.
- | epirubicin / Generic mfg.
Journal: Correction for Ferreira et al., "Computational Chemogenomics Drug Repositioning Strategy Enables the Discovery of Epirubicin as a New Repurposed Hit for Plasmodium falciparum and P. vivax". (Pubmed Central) - Oct 23, 2020
Our study identified potential mechanisms for rational development of strategies to mitigate anthracycline-induced cardiomyopathy. No abstract available
- | capecitabine / Generic mfg., docetaxel / Generic mfg.
Trial completion date, Trial primary completion date: Trial of Neoadjuvant Docetaxel (clinicaltrials.gov) - Oct 23, 2020
P2, N=170, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
No abstract available Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Dec 2020 --> Dec 2021
- | epirubicin / Generic mfg.
Journal: Histological findings in non-tumoral liver and tumor after chemoembolization with drug-eluting beads. (Pubmed Central) - Oct 22, 2020
DEB-TACE was performed using polyvinyl alcohol-based hydrogel microspheres loaded with epirubicin...Complete and partial histological tumor necrosis were found in three cases, respectively, in agreement with the complete and partial responses seen during the radiological evaluation. Histological examination of resected liver specimens after DEB-TACE showed substantial tumor necrosis without any severe inflammatory or destructive changes in the non-tumoral liver parenchyma.
- | Trial completion date, Trial primary completion date: COC-IDCB: A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast (clinicaltrials.gov) - Oct 21, 2020
P1, N=300, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Histological examination of resected liver specimens after DEB-TACE showed substantial tumor necrosis without any severe inflammatory or destructive changes in the non-tumoral liver parenchyma. Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Dec 2022
- | Journal, Immunogenic cell death: Inhibition of Immunosuppressive Tumors by Polymer-Assisted Inductions of Immunogenic Cell Death and Multivalent PD-L1 Crosslinking. (Pubmed Central) - Oct 20, 2020
Sequential treatment with a multivalent polymer-peptide antagonist to PD-L1 overcomes adaptive PD-L1 enrichment following chemotherapy, biases the recycling of PD-L1 to lysosome degradation via surface receptor crosslinking, and produces prolonged elimination of PD-L1 rather than the transient blocking afforded by standard anti-PD-L1 antibodies. Together, these findings established the polymer-facilitated tumor targeting of immunogenic drugs and surface crosslinking of PD-L1 as a potential new therapeutic strategy to propagate a long-term antitumor immunity, which might broaden the application of immunotherapy to immunosuppressive cancers.
- | Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) / Roche, Halozyme
Biomarker, Enrollment closed, Trial primary completion date, Metastases: IMMUN-HER: Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients (clinicaltrials.gov) - Oct 14, 2020
P2, N=65, Active, not recruiting, Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica
Together, these findings established the polymer-facilitated tumor targeting of immunogenic drugs and surface crosslinking of PD-L1 as a potential new therapeutic strategy to propagate a long-term antitumor immunity, which might broaden the application of immunotherapy to immunosuppressive cancers. Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2019 --> Mar 2021
- Herceptin (trastuzumab) / Roche
Trial completion date, Trial primary completion date, Tumor cell: Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells (clinicaltrials.gov) - Oct 13, 2020
P2, N=7, Active, not recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2019 --> Mar 2021 Trial completion date: Aug 2020 --> Dec 2020 | Trial primary completion date: Aug 2020 --> Dec 2020
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Combination therapy, Metastases: BERENICE: A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (clinicaltrials.gov) - Oct 13, 2020
P2, N=401, Completed, Sponsor: Hoffmann-La Roche
Trial completion date: Aug 2020 --> Dec 2020 | Trial primary completion date: Aug 2020 --> Dec 2020 Active, not recruiting --> Completed
- Herceptin (trastuzumab) / Roche
[VIRTUAL] Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial. (Channel 3) - Oct 11, 2020 - Abstract #EBCCI2020EBCC-I_1020;
These effects were particularly seen in patients with negative hormone receptors and dual anti-HER2 treatment. Although overall survival rates were not significantly different between arms, patients who reached pCR with L + T therapy were nearly doubled compared to the patients in the single agent arms.
- | Epidaza (chidamide) / Chipscreen
New trial: Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy (clinicaltrials.gov) - Oct 11, 2020
P=N/A, N=20, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- ||| Herceptin (trastuzumab) / Roche
Clinical, P3 data, Journal: Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial. (Pubmed Central) - Oct 10, 2020
The combination of DD chemotherapy and trastuzumab decreased the relative risk for relapse by 32% in comparison with standard treatment, a statistically nonsignificant difference. Its efficacy and safety merit further evaluation as part of both escalation and de-escalation strategies.
- zolbetuximab (IMAB362) / Astellas
[VIRTUAL] SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first:line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1246;
P2, P3
Background Fluorouracil, folinic acid, and oxaliplatin (mFOLFOX6) is accepted first-line therapy for advanced/metastatic G/GEJ...Phase II (NCT01630083) results showed prolonged survival of patients (pts) with CLDN18.2+ advanced G/GEJ treated with zolbe + epirubicin, oxaliplatin, and capecitabine (EOX) vs EOX alone...Funding: This study was funded by Astellas Pharma, Inc. Clinical trial identification: NCT03504397.
- zolbetuximab (IMAB362) / Astellas
[VIRTUAL] GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1243;
P2, P3
Funding: Astellas Pharma, Inc. Clinical trial identification: NCT03653507.
- zolbetuximab (IMAB362) / Astellas
[VIRTUAL] SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in firstline Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_881;
P2, P3
Fluorouracil, folinic acid, and oxaliplatin (mFOLFOX6) is accepted first-line therapy for advanced/metastatic G/GEJ...Phase II (NCT01630083) results showed prolonged survival of patients (pts) with CLDN18.2+ advanced G/GEJ treated with zolbe + epirubicin, oxaliplatin, and capecitabine (EOX) vs EOX alone...As of June 30, 2020, 190 sites have been initiated. This study was funded by Astellas Pharma, Inc.
- zolbetuximab (IMAB362) / Astellas
[VIRTUAL] GLOW: Phase III study of firstline zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_878;
P2, P3
As of June 30, 2020, 148 sites have been initiated. Astellas Pharma, Inc.
- zolbetuximab (IMAB362) / Astellas
[VIRTUAL] SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in firstline Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_508;
P2, P3
Fluorouracil, folinic acid, and oxaliplatin (mFOLFOX6) is accepted first-line therapy for advanced/metastatic G/GEJ...Phase II (NCT01630083) results showed prolonged survival of patients (pts) with CLDN18.2+ advanced G/GEJ treated with zolbe + epirubicin, oxaliplatin, and capecitabine (EOX) vs EOX alone...As of June 30, 2020, 190 sites have been initiated. This study was funded by Astellas Pharma, Inc.
- zolbetuximab (IMAB362) / Astellas
[VIRTUAL] GLOW: Phase III study of firstline zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_505;
P2, P3
As of June 30, 2020, 148 sites have been initiated. Astellas Pharma, Inc.
- | Halaven (eribulin mesylate) / Eisai
Journal: Dedifferentiated liposarcoma: when eribulin can make the difference. (Pubmed Central) - Oct 7, 2020
The CT scans performed every 3-4 months showed stable disease. After 13 months of treatment, a CT scan revealed disease progression and 10 days later, the patient died of bowel perforation and peritonitis.